ホーム › 骨髄異形成症候群 › フロリダ州 › Tampa
Tampa、FLにおける骨髄異形成症候群の臨床試験
Tampaとその周辺地域（約30マイル以内）の拠点で、骨髄異形成症候群に関する19件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
被験者募集中第2相
- Moffitt Cancer Center-International Plaza, Tampa
- Moffitt Cancer Center - McKinley Campus, Tampa
- Moffitt Cancer Center, Tampa
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
被験者募集中第1相
- Moffitt Cancer Center, Tampa
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
被験者募集中第1/2相
- Moffitt Cancer Center, Tampa
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
被験者募集中第3相
- Moffitt Cancer Center, Tampa
A Study of BGB-11417 in Participants With Myeloid Malignancies
被験者募集中第1/2相
- Tampa General Hospital, Tampa
A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
被験者募集中第1相
- Moffitt Cancer Center, Tampa
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
被験者募集中第1/2相
- Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
被験者募集中第3相
- Moffitt Cancer Center, Tampa
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
被験者募集中第2相
- H. Lee Moffitt Cancer Center and Research Center, Tampa
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
被験者募集中第1相
- H Lee Moffitt Cancer Center & Research Institute, Tampa
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
被験者募集中第2相
- Moffitt Cancer Center, Tampa
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
被験者募集中第1/2相
- Moffitt Cancer Center, Tampa
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
被験者募集中第2相
- Moffitt Cancer Center, Tampa
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
被験者募集中第1相
- Moffitt Cancer Center, Tampa
Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
被験者募集中第1相
- Moffitt Cancer Center, Tampa
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Tampa
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
被験者募集中第1相
- Moffitt Cancer Center, Tampa
Study of REM-422 in Patients With AML or Higher Risk MDS
被験者募集中第1相
- Moffitt Cancer Center, Tampa
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
被験者募集中第1/2相
- H. Lee Moffitt Cancer Center & Research Institute, Tampa
他の都市における骨髄異形成症候群の試験
- Houston, TX43件の研究
- Baldwin Park, CA26件の研究
- New York City, NY21件の研究
- Seattle, WA21件の研究
- Washington, DC20件の研究
- Boston, MA19件の研究
- Miami, FL17件の研究
- Columbus, OH14件の研究
- Durham, NC14件の研究
- St. Louis, MO13件の研究
- Atlanta, GA13件の研究
- Chicago, IL13件の研究
Tampaにおける他の研究
- 非小細胞肺癌51件の研究
- 乳がん43件の研究
- がん（全種類）39件の研究
- 大腸癌34件の研究
- 急性骨髄性白血病29件の研究
- 転移性癌29件の研究
- 肺がん29件の研究
- 膵臓がん26件の研究
- 卵巣がん21件の研究
- 悪性黒色腫19件の研究
- 前立腺がん18件の研究
- 心不全18件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。